1. Home
  2. TBPH vs KODK Comparison

TBPH vs KODK Comparison

Compare TBPH & KODK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • KODK
  • Stock Information
  • Founded
  • TBPH 2013
  • KODK 1880
  • Country
  • TBPH United States
  • KODK United States
  • Employees
  • TBPH N/A
  • KODK N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • KODK Business Services
  • Sector
  • TBPH Health Care
  • KODK Consumer Discretionary
  • Exchange
  • TBPH Nasdaq
  • KODK Nasdaq
  • Market Cap
  • TBPH 536.5M
  • KODK 469.3M
  • IPO Year
  • TBPH N/A
  • KODK N/A
  • Fundamental
  • Price
  • TBPH $11.15
  • KODK $6.30
  • Analyst Decision
  • TBPH Strong Buy
  • KODK
  • Analyst Count
  • TBPH 5
  • KODK 0
  • Target Price
  • TBPH $16.60
  • KODK N/A
  • AVG Volume (30 Days)
  • TBPH 245.1K
  • KODK 847.6K
  • Earning Date
  • TBPH 08-04-2025
  • KODK 08-07-2025
  • Dividend Yield
  • TBPH N/A
  • KODK N/A
  • EPS Growth
  • TBPH N/A
  • KODK N/A
  • EPS
  • TBPH N/A
  • KODK 0.52
  • Revenue
  • TBPH $65,266,000.00
  • KODK $1,041,000,000.00
  • Revenue This Year
  • TBPH $43.18
  • KODK N/A
  • Revenue Next Year
  • TBPH N/A
  • KODK N/A
  • P/E Ratio
  • TBPH N/A
  • KODK $12.01
  • Revenue Growth
  • TBPH 6.11
  • KODK N/A
  • 52 Week Low
  • TBPH $7.44
  • KODK $4.26
  • 52 Week High
  • TBPH $11.82
  • KODK $8.24
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 62.38
  • KODK 59.76
  • Support Level
  • TBPH $10.87
  • KODK $5.56
  • Resistance Level
  • TBPH $11.44
  • KODK $5.84
  • Average True Range (ATR)
  • TBPH 0.29
  • KODK 0.20
  • MACD
  • TBPH -0.00
  • KODK 0.06
  • Stochastic Oscillator
  • TBPH 71.92
  • KODK 90.28

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About KODK Eastman Kodak Company Common New

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

Share on Social Networks: